Fresenius Kabi Introduces Clofarabine Injection
First-to-market generic for CLOLAR® (clofarabine injection) now available
May 16, 2017
LAKE ZURICH, Ill., May 16, 2017 – Fresenius Kabi announced today the immediate availability in the United States of Clofarabine Injection. Fresenius Kabi Clofarabine Injection is available as a single dose vial containing 20 mg per 20 mL Clofarabine.
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
“Fresenius Kabi is pleased to introduce a generic version of this important pediatric cancer medicine,” said John Ducker, president and CEO of Fresenius Kabi USA. “Continuing to develop critical and accessible medicines for all patients is fundamental to the Fresenius Kabi mission of ‘caring for life’.”
Clofarabine Injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clofarabine.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.
CLOLAR® is a registered trademark of Genzyme Corporation.